drugset
drugset / Trial / NCT01423253

Major Depressive Disorder With Mixed Features - Extension

NCT01423253 ↗

Phase 3 Completed 48 enrolled Sumitomo Pharma America, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features over time.

Timeline

Start
2011-09
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule 20 mg Oral
Subject Lurasidone Small molecule 40 mg Oral
Subject Lurasidone Small molecule 60 mg Oral

Indications

major depressive disorder